Bivalirudin
- Product NDC
- 70860-402
- 11-digit product format
- 708600402
- Labeler code
- 70860
- Product ID
- 70860-402_556410e5-3149-4de4-8bea-aa90b7df437d
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- bivalirudin
- Dosage form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- INTRAVENOUS
- Labeler
- Athenex Pharmaceutical Division, LLC.
- Application
- ANDA210031
- Marketing category
- ANDA
- Marketing start
- 2019-11-30
- Marketing end
- 0000-00-00
- Substance
- BIVALIRUDIN
- Active strength
- 250 mg/1
- Pharmacologic classes
- Anti-coagulant [EPC],Direct Thrombin Inhibitor [EPC],Thrombin Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2020-12-31
- Current FDA listing
- Historical FDA.report record
FDA-Initiated Inactive NDC Indexing#
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 70860-402 | BIVALIRUDIN INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ATHENEX PHARMACEUTICAL DIVISION, LLC.] | 2 | Legacy NDC | 20240304_65b6f8fc-ae1f-45d6-9b7a-8bb3cc279f8f.zip |
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 70860-402-10 | 70860040210 | 10 VIAL, SINGLE-DOSE in 1 CARTON (70860-402-10) > 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE (70860-402-41) | 2019-11-30 | 0000-00-00 | No | No | Current |